Patents Assigned to Incyte Pharmaceuticals
-
Patent number: 6183968Abstract: The present invention relates to a composition comprising a plurality of polynucleotide probes. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to a method for selecting polynucleotide probes for the composition.Type: GrantFiled: March 25, 1999Date of Patent: February 6, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Jennifer L. Hillman, Henry Yue, Roopa Reddy, Karl J. Guegler, Mariah R. Baughn
-
Patent number: 6180342Abstract: The invention provides human vacuolar proton ATPase subunits (VATPS) and polynucleotides which identify and encode VATPS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of VATPS.Type: GrantFiled: June 17, 1998Date of Patent: January 30, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Y. Tom Tang, Preeti Lal, Neil C. Corley, Karl J. Guegler, Chandra Patterson
-
Patent number: 6177546Abstract: The invention provides a human glutathione-S-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HGST.Type: GrantFiled: December 22, 1999Date of Patent: January 23, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Henry Yue, Neil C. Corley, Purvi Shah
-
Patent number: 6174702Abstract: The invention provides a human PINCH protein homolog (PINCH-PH) and polynucleotides which identify and encode PINCH-PH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PINCH-PH.Type: GrantFiled: January 16, 1998Date of Patent: January 16, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Karl J. Guegler, Neil C. Corley
-
Patent number: 6171790Abstract: The invention provides human protease associated proteins (HPRAP) and polynucleotides which identify and encode HPRAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HPRAP.Type: GrantFiled: May 1, 1998Date of Patent: January 9, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Y. Tom Tang, Preeti Lal, Neil C. Corley, Karl J. Guegler, Chandra Patterson
-
Patent number: 6171843Abstract: The invention provides human peptidyl-prolyl isomerases (HPPIP) and polynucleotides which identify and encode HPPIP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HPPIP.Type: GrantFiled: June 1, 1998Date of Patent: January 9, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Neil C. Corley, Chandra Patterson, Mariah R. Baughn
-
Patent number: 6172199Abstract: The present invention provides a polynucleotide (ubcp) which identifies and encodes a novel ubiquitin-conjugating enzyme (UBCP). The invention provides for genetically engineered expression vectors and host cells comprising the nuclei acid sequence encoding UBCP. The invention also provides for the use of substantially purified UBCP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of UBCP. Additionally, the invention provides for the use of antisense molecules to ubcp in pharmaceutical compositions for treatment of diseases associated with the expression of UBCP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ubcp or anti-UBCP antibodies which specifically bind to UBCP.Type: GrantFiled: May 25, 1999Date of Patent: January 9, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Surya K. Goli, Jennifer L. Hillman
-
Patent number: 6171815Abstract: The present invention provides a human sulfonylurea receptor (SURH) and the polynucleotides which identify and encode SURH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding SURH and methods for producing the protein. The invention also provides pharmaceutical compositions containing SURH, agonists to SURH, or antagonists to SURH, and in the use of such compositions for the prevention or treatment of diseases associated with the expression of SURH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding SURH for the treatment of diseases associated with the expression of SURH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding SURH, or anti-SURH antibodies which specifically bind to SURH.Type: GrantFiled: October 2, 1996Date of Patent: January 9, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Olga Bandman, Roger Coleman
-
Patent number: 6168933Abstract: The invention provides a mammalian nucleic acid molecule and fragments thereof. It also provides for the use of the nucleic acid molecule for the characterization, diagnosis, evaluation, treatment, or prevention of conditions, diseases and disorders associated with gene expression and for the production of a model system. The invention additionally provides expression vectors and host cells for the production of the protein encoded by the mammalian nucleic acid molecule.Type: GrantFiled: June 8, 1999Date of Patent: January 2, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Matthew R. Kaser, Jennifer L. Hillman, Mariah R. Baughn
-
Patent number: 6165767Abstract: The invention provides human protein phosphatase-related molecules (PPRM) and polynucleotides which identify and encode PPRM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of PPRM.Type: GrantFiled: March 20, 1998Date of Patent: December 26, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Henry Yue, Neil C. Corley, Karl J. Guegler, Mariah Baughn
-
Patent number: 6162601Abstract: The invention provides a human pinin splice variant (PNIN) and polynucleotides which identify and encode PNIN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PNIN.Type: GrantFiled: August 8, 1997Date of Patent: December 19, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Purvi Shah
-
Patent number: 6160104Abstract: The present invention relates to a composition comprising a plurality of polynucleotide targets. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to methods for screening compounds and therapeutic treatments for toxicological responses.Type: GrantFiled: October 13, 1998Date of Patent: December 12, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Mary Jane Cunningham, Gary B. Zweiger, Scott R. Panzer, Jeffrey J. Seilhamer
-
Patent number: 6160105Abstract: The present invention relates to a composition comprising a plurality of polynucleotide targets. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to methods for screening compounds and therapeutic treatments for toxicological responses.Type: GrantFiled: October 13, 1998Date of Patent: December 12, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Mary Jane Cunningham, Gary B. Zweiger, Scott R. Panzer, Jeffrey J. Seilhamer
-
Patent number: 6156523Abstract: The invention provides human serine/threonine protein kinases (HSTK) and polynucleotides which identify and encode HSTK. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HSTK.Type: GrantFiled: September 16, 1998Date of Patent: December 5, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Y. Tom Tang, Surya K. Goli, Neil C. Corley, Karl J. Guegler, Gina A. Gorgone, Jennifer L. Hillman
-
Patent number: 6153195Abstract: Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds .beta.-galactoside-containing moieties independent of the presence or absence of Ca.sup.+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.Type: GrantFiled: September 25, 1996Date of Patent: November 28, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jeffrey J. Seilhammer, Glenn Nedwin, Tim Bringman, Pierre-Olivier Couraud
-
Patent number: 6153423Abstract: The invention provides a human myotrophin (MYO1) and polynucleotides which identify and encode MYO1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of MYO1.Type: GrantFiled: September 19, 1997Date of Patent: November 28, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
-
Patent number: 6146624Abstract: The invention provides a human ubiquitin-conjugating enzyme (HUBI) and polynucleotides which identify and encode HUBI. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HUBI.Type: GrantFiled: July 22, 1999Date of Patent: November 14, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Jennifer L. Hillman, Neil C. Corley
-
Patent number: 6143867Abstract: The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBPH and a method for producing EBPH. The invention also provides for use of EBPH and agonists, antibodies or antagonists specifically binding EBPH, in the prevention and treatment of diseases associated with expression of EBPH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding EBPH for the treatment of diseases associated with the expression of EBPH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding EBPH.Type: GrantFiled: March 17, 1998Date of Patent: November 7, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventor: Ingrid E. Akerblom
-
Patent number: 6143870Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel thrombin receptor homolog (TRH) expressed in human liver. The present invention also provides for antisense molecules to the nucleotide sequences which encode TRH, diagnostic tests based on TRH encoding nucleic acid molecules, expression vectors for the production of purified TRH, antibodies capable of binding specifically to TRH, hybridization probes or oligonucleotides for the detection of TRH-encoding nucleotide sequences, genetically engineered host cells for the expression of TRH, and antagonists, antibodies and inhibitors with specific binding activity for the polypeptide TRH.Type: GrantFiled: December 21, 1998Date of Patent: November 7, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Roger Coleman, Janice Au-Young, Olga Bandman, Jeffrey J. Seilhamer
-
Patent number: 6143544Abstract: The invention provides a new human lysophospholipase (JHLP) and polynucleotides which identify and encode IHLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating inflammation and disorders associated with expression of IHLP.Type: GrantFiled: June 19, 1997Date of Patent: November 7, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley, Lynn E. Murry